Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Pipeline Review, H2 2016’, provides in depth analysis on Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted pipeline therapeutics.

The report provides comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)

The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects

The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Akari Therapeutics, Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

Epirus Biopharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

InflaRx GmbH

Novartis AG

Noxxon Pharma AG

Ophthotech Corp.

Ra Pharmaceuticals, Inc.

Swedish Orphan Biovitrum AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Overview 10

Therapeutics Development 11

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Stage of Development 11

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Therapy Area 12

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Indication 13

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Companies 17

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Universities/Institutes 21

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment 23

Assessment by Monotherapy/Combination Products 23

Assessment by Mechanism of Action 24

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development 29

Akari Therapeutics, Plc 29

Alexion Pharmaceuticals Inc 30

Alnylam Pharmaceuticals, Inc. 31

Amgen Inc. 32

Epirus Biopharmaceuticals, Inc. 33

F. Hoffmann-La Roche Ltd. 34

InflaRx GmbH 35

Novartis AG 36

Noxxon Pharma AG 37

Ophthotech Corp. 38

Ra Pharmaceuticals, Inc. 39

Swedish Orphan Biovitrum AB 40

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles 41

AcPepA - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ALN-CC5 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ALXN-1007 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

ALXN-1210 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ALXN-5500 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

avacincaptad pegol sodium - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Bikaciomab - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

BikajuMab - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Coversin - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Coversin LA - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

eculizumab - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

eculizumab biosimilar - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

eculizumab biosimilar - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

IFX-1 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

IFX-2 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Mubodina - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

NM-9405 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

NOXD-19 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

NOXD-20 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

NOXD-21 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Protein to Inhibit Complement C5 for Immunology - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

RA-101295 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

RA-101348 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

RA-101495 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

RO-7112689 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

SOBI-005 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Autoimmune Disorders - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

tesidolumab - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Projects 91

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products 94

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Featured News & Press Releases 95

Sep 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria 95

Aug 29, 2016: European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease 95

Jul 13, 2016: Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria 96

Jul 12, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria 96

Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress 97

Jul 06, 2016: Federal Court Dismisses Challenge to Constitutionality of Federal Government's Drug Price Watchdog 99

Jul 06, 2016: Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin 99

Jun 11, 2016: Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/2 Study 100

Jun 10, 2016: Alexion Pharmaceuticals Presented data on ALXN1007 at 21st Congress of the European Hematology Association 102

Jun 10, 2016: Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH 103

Jun 10, 2016: Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association 104

Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery 105

Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG) 106

Jun 03, 2016: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data 108

Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) 108

Appendix 109

Methodology 109

Coverage 109

Secondary Research 109

Primary Research 109

Expert Panel Validation 109

Contact Us 109

Disclaimer 110

List of Tables

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Products under Investigation by Universities/Institutes, H2 2016 22

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Pipeline by Akari Therapeutics, Plc, H2 2016 29

Pipeline by Alexion Pharmaceuticals Inc, H2 2016 30

Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 31

Pipeline by Amgen Inc., H2 2016 32

Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 33

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 34

Pipeline by InflaRx GmbH, H2 2016 35

Pipeline by Novartis AG, H2 2016 36

Pipeline by Noxxon Pharma AG, H2 2016 37

Pipeline by Ophthotech Corp., H2 2016 38

Pipeline by Ra Pharmaceuticals, Inc., H2 2016 39

Pipeline by Swedish Orphan Biovitrum AB, H2 2016 40

Dormant Projects, H2 2016 91

Dormant Projects (Contd..1), H2 2016 92

Dormant Projects (Contd..2), H2 2016 93

Discontinued Products, H2 2016 94

List of Figures

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports